AMRN Amarin Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: AMRN

Price (delayed)

$12.13

Market cap

$252.35M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1

Enterprise value

$100.99M

?
Relative Growth: Rel. Growth: 9
Relative Strength: Rel. Strength: 28
Relative Valuation: Rel. Valuation: 23
Relative Profitability: Rel. Profitability: 39

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional ...

Highlights
AMRN's net income has soared by 78% YoY and by 29% from the previous quarter
The company's EPS has surged by 76% YoY and by 29% QoQ
AMRN's gross margin is up by 5% year-on-year but it is down by 2.6% since the previous quarter
The revenue is down by 22% year-on-year and by 5% since the previous quarter
Amarin's gross profit has decreased by 18% YoY and by 8% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.amarincorp.com
Peers: ABBV ALKS TEVA AZN

Key stats

What are the main financial stats of AMRN

AMRN stock price

How has the Amarin stock price performed over time
Intraday
0.17%
1 week
0.33%
1 month
-1.78%
1 year
-25.54%
YTD
-13.08%
QTD
-6.69%

Financial performance

How have Amarin's revenue and profit performed over time
Revenue
$176.11M
Gross profit
$72.11M
Operating income
-$32.03M
Net income
-$19.14M
Gross margin
40.9%
Net margin
-10.9%
AMRN's net income has soared by 78% YoY and by 29% from the previous quarter
AMRN's net margin has surged by 71% year-on-year and by 25% since the previous quarter
AMRN's operating income has soared by 67% year-on-year and by 21% since the previous quarter
AMRN's operating margin has surged by 57% year-on-year and by 17% since the previous quarter

Price vs fundamentals

How does AMRN's price correlate with its fundamentals

Growth

What is Amarin's growth rate over time

Valuation

What is Amarin stock price valuation
P/E
N/A
P/B
0.58
P/S
1.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.57
The company's EPS has surged by 76% YoY and by 29% QoQ
AMRN's P/B is 28% below its 5-year quarterly average of 0.8 and 17% below its last 4 quarters average of 0.7
The equity has declined by 3.2% year-on-year
The revenue is down by 22% year-on-year and by 5% since the previous quarter
The P/S is 4% less than the last 4 quarters average of 1.5 but 2.9% more than the 5-year quarterly average of 1.4

Efficiency

How efficient is Amarin business performance
AMRN's ROE has soared by 77% YoY and by 28% from the previous quarter
Amarin's ROA has soared by 77% YoY and by 29% from the previous quarter
The ROIC has soared by 77% YoY and by 31% QoQ
The company's return on sales has surged by 74% YoY and by 31% QoQ

Dividends

What is AMRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMRN.

Financial health

How did Amarin financials performed over time
AMRN's quick ratio is up by 9% year-on-year
AMRN's total liabilities is down by 6% year-on-year but it is up by 4.9% since the previous quarter
AMRN's debt is 99% smaller than its equity
AMRN's debt is down by 20% year-on-year
The equity has declined by 3.2% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.